---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-24-000061"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2024-05-17T23:59:59+00:00"
generated_at: "2026-06-01T16:55:46.405760+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Senti Bio appoints Kanya Rajangam as President; CEO Lu remains CEO

## Summary
- Tim Lu stepped down as President effective May 14, 2024, but continues as CEO.
- Kanya Rajangam, M.D., Ph.D., appointed President; she remains Head of R&D and CMO.
- Rajangam joined Senti in July 2022; prior CMO at Nkarta (NKTX) and Atara (ATRA).
- Her compensation includes $490K base salary, 40% target bonus, option grant, and severance per 2022 offer letter.

## SEC filing metadata
- accession: 0001854270-24-000061
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2024-05-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000061/0001854270-24-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000061/snti-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-24-000061
- JSON: https://secwatch.observer/filing/0001854270-24-000061.json
- Plain text: https://secwatch.observer/filing/0001854270-24-000061.txt

## Key facts
- Executive change
  Kanya Rajangam was appointed as President at Senti Biosciences, Inc..
  - Action: appointed
  - Role: President
  source text: Kanya Rajangam, M.D., Ph.D., the Company's Head of Research and Development, and Chief Medical Officer, was appointed to serve as the President of the Company, effective as of May 14, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000061/0001854270-24-000061-index.htm
- Executive change
  Timothy Lu changed role as President at Senti Biosciences, Inc..
  - Action: stepped down
  - Role: President
  source text: Timothy Lu, M.D., Ph.D., Chief Executive Officer and President, stepped down as President
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000061/0001854270-24-000061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.